Fundraising Fox
Axelyf
Chestnut Hill, US · Founded 2025 · Delaware corporation · 14 employees on LinkedIn · 1 known investors
Find your way into Axelyf
Sign up to see every warm intro you have to Axelyf
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Axelyf team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Axelyf develops RNA medicines built on nanotechnology formulations and nucleic acid technologies, working across the drug development pathway from CMC and clinical pharmacology to computational sciences. The company focuses on RNA therapeutics platform development and associated therapeutic programs.
Founders & leadership
Axelyf was founded in 2025 by Orn Almarsson.
OA
Orn AlmarssonCo-FounderOrn Almarsson is leading Axelyf, an RNA medicine company developing therapies for autoimmune disease and oncology using lipid nanoparticle technology. He previously served as head of delivery science and process chemistry at Moderna, where he contributed to lipid nanoparticle development, and earlier held roles at Merck in the mid-1990s.
LW
Leslie WilliamsNamed on SEC filing
Board
AB
JL
John LucasBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$7.5M disclosed across 2 rounds · 2025–2026
▶$2.6MraisedOct 2026 · 8 investors · BiotechnologyRule 506(b)
▶$2.6MraisedOct 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Orn AlmarssonExecutive Officer, Director, Promoter
- Leslie WilliamsDirector
- Arni BlondalDirector
- Offering amount
- $2.7M
- Amount sold
- $2.6M
- First sale
- Oct 2026
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
▶$4.8MraisedAug 2025 · 37 investors · BiotechnologyRule 506(b)
▶$4.8MraisedAug 2025 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John LucasDirector
- Arni BlondalDirector
- Orn AlmarssonExecutive Officer, Director, Promoter
- Offering amount
- $6.3M
- Amount sold
- $4.8M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Axelyf do?
- Axelyf develops RNA medicines built on nanotechnology formulations and nucleic acid technologies, working across the drug development pathway from CMC and clinical pharmacology to computational sciences. The company focuses on RNA therapeutics platform development and associated therapeutic programs.
- Who founded Axelyf?
- Axelyf was founded by Orn Almarsson in 2025.
- Who are Axelyf's investors?
- Axelyf's investors include Brunnur Ventures GP.
- How much funding has Axelyf raised?
- Axelyf has disclosed $7.5M raised across 2 rounds.
- Where is Axelyf headquartered?
- Axelyf is headquartered in Chestnut Hill, US.